Jco precision oncology.
PURPOSE With the recent approval of the KRAS G12C inhibitor sotorasib for patients with advanced KRAS G12C-mutant non–small cell lung cancer (NSCLC), there is a new need to identify factors associated with activity and toxicity among patients treated in routine practice. MATERIALS AND METHODS We conducted a multicenter retrospective study of patients treated with sotorasib outside of ...
DOI: 10.1200/PO.16.00066 JCO Precision Oncology - published online June 27, 2017Key Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ...Jul 6, 2023 · Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ... The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor …The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor …
DOI: 10.1200/PO.21.00047 JCO Precision Oncology no. 5 (2021) 808-816. Published online May 12, 2021. PMID: 34994613. Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs) Kimberly Perez, MD 1, 2. x. Kimberly Perez. Search for articles by this author ...The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor …
PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS We conducted a retrospective multicenter study to identify patients with advanced prostate cancer who harbored somatic loss-of-function CDK12 ...
Jan 6, 2022 · An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. Le Tourneau et al. Published online: August 8, 2022. DOI: 10.1200/PO.19.00292 JCO Precision Oncology no. 4 (2020) 244-257. Published online March 27, 2020. PMID: 32923909. Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy Shunying Li, PhD 1, 2. x. Shunying Li. Search for articles by this author ...The liquid biopsy NGS assay demonstrated excellent concordance with tissue profiling in this multicenter, prospective, clinical validation study, with sensitivity and specificity equivalent to Food and Drug Administration-approved single-gene ctDNA assays. The use of plasma-based molecular profiling …DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017
DOI: 10.1200/PO.22.00317 JCO Precision Oncology no. 7 (2023) e2200317. Published online April 26, 2023. PMID: 37099733. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis ...
DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019
Given the high attrition rate of de novo drug discovery and limited efficacy of single-agent therapies in cancer treatment, combination therapy prediction through in silico drug repurposing has risen as a time- and cost-effective alternative for identifying novel and potentially efficacious therapies for cancer. The purpose of this review is to provide an introduction to computational methods ...This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines.WebJCO Precision Oncology showcases high-quality, original documents where all submitted articles are peer reviewed to provide the best quality. The journal welcomes submissions from the research community where emphasis will be placed on the originality and the practical impact of the reported research.15 Mar 2023 ... Elypta study published in JCO Precision Oncology using GAGome to predict and monitor responses of patients with Metastatic Renal Cell ...PURPOSE Acute lymphoblastic leukemia (ALL) is the most prevalent cause of childhood cancer and requires a long course of therapy consisting of three primary phases with interval intensification blocks. Although these phases are necessary to achieve remission, the primary chemotherapeutic agents have potentially serious toxicities, which may lead to delays or discontinuations of therapy. The ...
DOI: 10.1200/PO.18.00247 JCO Precision Oncology - published online April 25, 2019 PMID: 32914012. Precision Oncology in Sarcomas: Divide and Conquer Roberto Carmagnani Pestana, MD 1. x. Roberto Carmagnani Pestana. Search for articles by this author ; Roman Groisberg, MD 1. x. Roman Groisberg ...DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsAlberta Precision Labs (APL) is a medical laboratory that offers a wide range of diagnostic tests and services. If you need to book an appointment with APL, there are a few things you should know before you go.The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor gene sequencing panels have made this a challenging time for ...DOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA SubstudyWebDOI: 10.1200/PO.23.00092 JCO Precision Oncology no. 7 (2023) e2300092. Published online July 6, 2023. PMID: 37410975. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness ...This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. …
Purpose HER2 amplification has been implicated in resistance to therapy with anti–epidermal growth factor receptor antibodies (anti-EGFRabs) in metastatic colorectal cancer (mCRC). The purpose of the study was to validate the predictive impact of HER2 amplification in mCRC. Patients and Methods We analyzed patients with RAS/BRAF wild-type mCRC across two distinct cohorts. In cohort 1 (n = 98 ...The 2022 impact factor of JCO Precision Oncology is 3.6, making it among the top 4% journals. The journal covers the disciplines of Oncology.
Alberta Precision Labs (APL) is a medical laboratory that offers a wide range of diagnostic tests and services. If you need to book an appointment with APL, there are a few things you should know before you go.Key Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ...JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer.Precision oncology, where patients are given therapies on the basis of their genomic profile and disease trajectory, is rapidly evolving to become a pivotal part of cancer management, supported by the approval of many biomarker-matched targeted therapies and cancer immunotherapies by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). 1 Driven by recent advances in ...JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of …This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. Research Funding: Ambry Genetics ...
Precision fabrication is a critical process in various industries, including manufacturing, construction, and automotive. Whether it’s building structures, creating intricate metal designs, or repairing equipment, welding plays a crucial ro...
Purpose HER2 amplification has been implicated in resistance to therapy with anti–epidermal growth factor receptor antibodies (anti-EGFRabs) in metastatic colorectal cancer (mCRC). The purpose of the study was to validate the predictive impact of HER2 amplification in mCRC. Patients and Methods We analyzed patients with RAS/BRAF wild-type mCRC across two distinct cohorts. In cohort 1 (n = 98 ...
Jan 6, 2022 · DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994 Apr 22, 2021 · PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ... 24-hour private clinics and medical centers 49 Ambulatory surgery in Tashkent, in Uzbekistan 4 Analyses of blood by rubella - services 3 Analysis of allergy - services 7 …DOI: 10.1200/PO.22.00363 JCO Precision Oncology no. 7 (2023) e2200363. Published online May 24, 2023. PMID: 37224427. Exceptional Response to Dual Colony-Stimulating ...DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994WebDOI: 10.1200/PO.21.00463 JCO Precision Oncology no. 6 (2022) e2100463. Published online April 27, 2022. Published online April 27, 2022. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast …Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post As such, scientific outlets in general, and JCO Precision Oncology in particular, owe an immense debt of gratitude to our volunteer peer reviewers. JCO PO strives to provide the highest quality peer review, so in recognition of Peer Review Week 2023 and its theme of Peer Review and The Future of Publishing, ...JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not …This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe. David Cohn. Consulting or Advisory Role: …Apr 23, 2020 · PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC). Overexpression, amplification, and point mutations in HER2 have been described in patients with NSCLC; however, the potential roles of these alterations remain unclear. METHODS We summarize the evidence regarding the ... Aims & Scope of the Journal. JCO Precision Oncology publishes academic articles describing recent essential contributions in the areas of Biological Sciences, General …
PURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 insertion mutations are emerging as a distinct molecular subtype with expanding therapeutic options. We describe the molecular epidemiology and genomic features of …WebOncoTree is also used by OncoKB, 27 a precision oncology knowledge base containing information about the biological effects and clinical implications of genomic alterations in cancer. 28 OncoKB uses the OncoTree classifications in conjunction with genomic information (gene and alterations) to annotate therapeutic, prognostic, and …PURPOSE Precision medicine uses advanced molecular techniques to guide the use of targeted therapeutic drugs and is an emerging paradigm in pediatric oncology. Clinical evidence related to the efficacy of many novel targeted drugs, however, is currently very limited given the rarity of pediatric cancer and the lack of published evidence for the use of these drugs in children. This systematic ...The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor …Instagram:https://instagram. budwieser stocksan francisco 49ers joe montana jerseystock savehow to tell if its gold 詳細. タイトル. JCO precision oncology. JCO precision oncology. ... American Society of Clinical Oncology, publisher. ... Began with February 22, 2017. Began with ... nyse mpc financialsprana sustainability PURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we analyzed the implementation of a multidisciplinary PMed program ...Purpose HER2 amplification has been implicated in resistance to therapy with anti–epidermal growth factor receptor antibodies (anti-EGFRabs) in metastatic colorectal cancer (mCRC). The purpose of the study was to validate the predictive impact of HER2 amplification in mCRC. Patients and Methods We analyzed patients with RAS/BRAF wild-type mCRC across two distinct cohorts. In cohort 1 (n = 98 ... best commercial lenders Stage 4 is the final stage of most cancers that have spread to other areas of the body, states the American Society of Clinical Oncology. Cancer stages are usually determined by the size, growth and spread of the cancer.DOI: 10.1200/PO.20.00008 JCO Precision Oncology no. 4 (2020) 393-410. Published online April 23, 2020. PMID: 35050740. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational Profiles ...DOI: 10.1200/PO.23.00338 JCO Precision Oncology no. 7 (2023) e2300338. Published online December 1, 2023. Published online December 1, 2023. Homologous Recombination Deficiency Across Subtypes of …